^
abGelli D, Vignati E (1976). "Metabolic studies with formebolone (2-formyl-17 (alpha)-methyl-androsta-1,4-diene-11 (alpha), 17 (beta)-diol-3-one) in humans". The Journal of International Medical Research. 4 (2): 96–105.
doi:
10.1177/030006057600400203.
PMID799985.
S2CID86157607.
^Cerutti S, Forlani A, Galimberti E (1976). "Anticatabolic action of formebolone in the castrated rat treated with dexamethasone". Arzneimittel-Forschung. 26 (9): 1673–1677.
PMID1036699.
^Felippone F, Resnati G, Scolastico C, Tronconi G (March 1984). "Synthesis of 2-carboxy-11 beta, 17 beta-dihydroxy-17-methyl-1, 4-androstadien-3-one and related compounds". Steroids. 43 (3): 271–282.
doi:
10.1016/0039-128x(84)90045-x.
PMID6523544.
S2CID54289377.
^Dahlberg E, Snochowski M, Gustafsson JA (April 1981). "Regulation of the androgen and glucocorticoid receptors in rat and mouse skeletal muscle cytosol". Endocrinology. 108 (4): 1431–1440.
doi:
10.1210/endo-108-4-1431.
PMID6970661.
^Souness GW, Latif SA, Laurenzo JL, Morris DJ (April 1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat". Endocrinology. 136 (4): 1809–1812.
doi:
10.1210/endo.136.4.7895695.
PMID7895695.
^Souness GW, Morris DJ (March 1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat". Hypertension. 27 (3 Pt 1): 421–425.
doi:
10.1161/01.hyp.27.3.421.
PMID8698448.